Search
R-348
go.drugbank.com/drugs/DB06321InvestigationalSynonyms: 5-Fluoro-N-(4-methyl-3-propionylaminosulfonylphenyl)-N'-(4-(prop-2-ynyloxy)phenyl)-2,4-pyrimidinediamineMaytansine
go.drugbank.com/drugs/DB19582InvestigationalMaytansine is under investigation in clinical trial NCT04189211 (A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients).
Chlorcyclizine
go.drugbank.com/drugs/DB08936ApprovedChlorcyclizine also has some local anesthetic, anticholinergic, and antiserotonergic properties, and can be used as an antiemetic.
RD06-04
go.drugbank.com/drugs/DB24647InvestigationalRD06-04 is under investigation in clinical trial NCT06986018 (Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV).
Zandatrigine
go.drugbank.com/drugs/DB19051InvestigationalZandatrigine is under investigation in clinical trial NCT05226780 (Extension Study to Evaluate How Safe and Tolerable NBI-921352 Is as an Adjunctive Therapy for Participants With SCN8A-DEE).
Synonyms: Benzenesulfonamide, 2-fluoro-5-methyl-4-(methyl((3s)-1-(phenylmethyl)-3-pyrrolidinyl)amino)-n-4-thiazolyl-Indoprofen
go.drugbank.com/drugs/DB08951ApprovedWithdrawnFollowing reports of adverse reactions including reports of carcinogenicity in animal studies it was withdrawn from the market worldwide.
Pexelizumab
go.drugbank.com/drugs/DB04949InvestigationalPexelizumab is a humanized monoclonal antibody used as an immunosuppressive drug. It is being investigated by Alexion Pharmaceuticals.
NAV 1800
go.drugbank.com/drugs/DB05437ExperimentalRIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal cancer.
ABX1100
go.drugbank.com/drugs/DB17655InvestigationalABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle.
Ocriplasmin
go.drugbank.com/drugs/DB08888ApprovedWithdrawnFDA approved in October 17, 2012. … Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system.